Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc, dated August 21, 2017, reports a significant corporate governance and executive leadership change. The Board of Directors appointed Dr. David Horn Solomon as a Class A director and Chief Executive Officer, effective August 28, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of the new CEO's employment agreement rather than financial performance.
Material Changes
The primary material change is the appointment of Dr. David Horn Solomon as CEO and Board member. The filing details the specific terms of his Executive Employment Agreement, including:
- Compensation: Annual base salary of $500,000, subject to annual review.
- Bonuses: One-time cash bonus of $50,000 plus relocation expenses up to $80,000 (grossed up for taxes). Eligible for an annual performance bonus with a target of 40% of base salary.
- Equity: Stock option to purchase 26,000,000 Ordinary Shares (260,000 ADSs) with a 10-year term, vesting ratably over four years.
- Term: Two-year initial term with automatic one-year renewals.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or general risk factors. However, it outlines specific termination contingencies and severance packages:
- Termination without Cause/Good Reason: Entitles Dr. Solomon to 12 months of base salary, the target annual performance bonus, and 12 months of medical insurance premiums.
- Change in Control: If termination occurs within one year of a change in control and the company valuation is at least $150 million, severance increases to 18 months of base salary, 1.5 times the target bonus, and 18 months of medical insurance.
- Resignation: Termination of employment constitutes automatic resignation from the Board.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 26 million share option grant.
- Confirm the total potential cash outlay for relocation expenses and the one-time signing bonus.
- Review the specific definitions of "Cause" and "Good Reason" in the full Employment Agreement (Exhibit 10.1) to understand severance triggers.
- Assess the impact of the $150 million valuation threshold on potential change-of-control severance liabilities.